News, features, and commentary about cancer-related issues ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ... Read More The post Health Check: Telix jumps first hurdle with its ...

The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...

Targeted ultrasound therapy offers a less invasive prostate cancer treatment designed to minimize disruption to daily life.

Research team at OncoRay identifies MMP11 as a promising biomarker for liquid biopsy in prostate cancer Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In ...

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

MARCAP investigators conducted the first individual patient data meta-analysis of randomized trials (POSEIDON) evaluating the use and duration hormone therapy with postoperative radiation therapy in ...

A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to post ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...

Oxybutynin significantly reduced hot flash frequency and severity compared with placebo among men with prostate cancer ...